首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | IL13 |
| Uniprot No | P35225 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 25-146aa |
| 氨基酸序列 | LTCLGGFASP GPVPPSTALR ELIEELVNIT QNQKAPLCNG SMVWSINLTA GMYCAALESL INVSGCSAIE KTQRMLSGFC PHKVSAGQFS SLHVRDTKIE VAQFVKDLLL HLKKLFREGR FN |
| 预测分子量 | 13 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是与 **IL-13重组蛋白**相关的3篇代表性文献摘要简述：
---
1. **文献名称**：*"IL-13 receptors and signaling pathways: An evolving web"*
**作者**：Hershey, G.K. 等
**摘要**：综述了IL-13的受体复合物(包括IL-13Rα1和IL-13Rα2)的结构与功能，解析了其通过JAK-STAT信号通路调控炎症反应和纤维化的分子机制，并讨论了重组IL-13蛋白在实验模型中的应用。
2. **文献名称**：*"Therapeutic targeting of IL-13 in asthma: A promising approach"*
**作者**：Wills-Karp, M. 等
**摘要**：通过动物模型和体外实验，证实重组IL-13蛋白可诱导气道高反应性和黏液分泌，提示其在哮喘病理中的核心作用。研究还评估了靶向IL-13的单抗类药物对炎症的抑制作用。
3. **文献名称**：*"IL-13 promotes tissue fibrosis via TGF-β1 activation in experimental liver injury"*
**作者**：Fichtner-Feigl, S. 等
**摘要**：在小鼠肝纤维化模型中，重组IL-13蛋白直接激活TGF-β1信号，加剧胶原沉积和纤维化进程，为靶向IL-13治疗器官纤维化提供了理论依据。
---
如需具体文献年份或补充更多研究，可进一步说明!
Interleukin-13 (IL-13) is a pleiotropic Th2 cytokine central to type 2 immune responses, primarily produced by activated CD4+ T cells, mast cells, basophils, and innate lymphoid cells. It plays critical roles in allergic inflammation, tissue remodeling, and host defense against helminth infections by regulating immune cell communication and effector functions. IL-13 signals through a heterodimeric receptor complex comprising IL-13Rα1 and IL-4Rα, activating JAK-STAT pathways (mainly STAT6) to drive gene expression linked to mucus production, smooth muscle hyperreactivity, and fibrosis. Dysregulated IL-13 signaling is implicated in asthma, atopic dermatitis, eosinophilic esophagitis, and fibrotic diseases.
Recombinant IL-13 proteins are engineered using bacterial (e.g., *E. coli*), mammalian, or insect expression systems to preserve native structure and bioactivity. These proteins typically lack post-translational modifications when prokaryotically expressed but retain receptor-binding capacity. They serve as essential tools for *in vitro* studies (e.g., cell differentiation assays), *in vivo* disease modeling, and therapeutic target validation. Notably, IL-13 inhibitors like lebrikizumab and tralokinumab (monoclonal antibodies targeting IL-13 or its receptor) have emerged as biologics for asthma and atopic dermatitis, underscoring the therapeutic relevance of recombinant IL-13 in drug discovery. Researchers also utilize tagged versions (e.g., His, Fc fusions) for purification, detection, or prolonged half-life in experimental settings. Quality assessments include endotoxin testing, receptor-binding ELISAs, and functional assays measuring STAT6 phosphorylation or epithelial cell responses.
×
